Dr. Farshid Dayyani
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
About Farshid Dayyani
Education:
- Earned an MD from Ludwig Maximilian University of Munich, Germany (Class of 2002).
- Completed Residency in Internal Medicine at Beth Israel Deaconess Medical Center (2006-2008).
- Undertook a Fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/MD Anderson Cancer Center (2008-2011).
Experience:
- Serves as Associate Director for Translational Science at UC Irvine Health/Chao Family Comprehensive Cancer Center.
- Holds the position of Medical Director for the Stern Center for Cancer Clinical Trials & Research.
- Appointed Chief of the Division of Hematology/Oncology at UC Irvine School of Medicine.
- Actively involved in clinical trials as Principal Investigator.
Area of expertise
Pancreatic Cancer
Farshid Dayyani has run 8 trials for Pancreatic Cancer. Some of their research focus areas include:
Cancer
Farshid Dayyani has run 8 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
UC Irvine Health/Chao Family Comprehensive Cancer Center
UCI Health - Chao Family Comprehensive Cancer Center And Ambulatory Care
Clinical Trials Farshid Dayyani is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Chemotherapy Decision Test
for Gastroesophageal Cancer
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Recruiting
1 award
Phase 1
More about Farshid Dayyani
Clinical Trial Related
3 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 11 Active Clinical Trials
Treatments Farshid Dayyani has experience with
- Nivolumab
- Irinotecan
- Cabozantinib
- TAS-102
- Docetaxel
- Paclitaxel
Breakdown of trials Farshid Dayyani has run
Pancreatic Cancer
Cancer
Stomach Cancer
Esophageal cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Farshid Dayyani specialize in?
Farshid Dayyani focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Farshid Dayyani currently recruiting for clinical trials?
Yes, Farshid Dayyani is currently recruiting for 11 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Farshid Dayyani has studied deeply?
Yes, Farshid Dayyani has studied treatments such as Nivolumab, Irinotecan, Cabozantinib.
What is the best way to schedule an appointment with Farshid Dayyani?
Apply for one of the trials that Farshid Dayyani is conducting.
What is the office address of Farshid Dayyani?
The office of Farshid Dayyani is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.